Page 10 - Practical Approaches to Managing Castration-Resistant Prostate Cancer (CRPC)

Managing Non-Metastatic Castration-

Resistant Prostate Cancer (nmCRPC)

Definition: Non-Metastatic Castration-

Resistant Prostate Cancer (nmCRPC)

• Testosterone ≤1.7 nmol/L AND
• Rising PSA (≥2 ng/mL) AND
• No visible metastases on CT scan (or MRI) and bone scan (BS)

• Also referred to as m0CRPC

nmCRPC Patient Identification and
Categorization of Disease Risk

• nmCRPC represents a state of progression where rising PSA is observed despite
testosterone levels ≤1.7 nmol/L
• Conventional imaging using CT scan (or MRI) and bone scan show no evidence
of metastatic disease

• Current management options take into consideration disease risk
(see algorithm on page 8)
• Patients should be categorized according to disease risk based on PSA doubling
time (PSADT)
– High-risk disease: PSADT ≤10 months
– Low-risk (non-high-risk) disease: PSADT >10 months

Practical Approaches to Managing CRPC 7